| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2a data readout example | CT2000 acute ocular pain; chronic ocular surface pain commonly associated with dry eye disease (moderate to severe dry eye disease with chronic eye pain) | Phase 1b/2a | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 1b/2a data readout example | CT2000 acute ocular pain; chronic ocular surface pain commonly associated with dry eye disease (moderate to severe dry eye disease with chronic eye pain) | Phase 1b/2a | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 1b/2a data readout example | CT2000 acute ocular pain; chronic ocular surface pain commonly associated with dry eye disease (moderate to severe dry eye disease with chronic eye pain) | Phase 1b/2a | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Pelthos Therapeutics Inc.$26.84
-1.82 (-6.35%)
Market Cap
92.66 M
EPS
-20.65
P/E Ratio
-
Value Trade
180.28 K
SEC Financials
Q1 2026Dilution Risk
Revenue
10.91 M
R&D Expenses
186.00 K
Operating CF
-13.13 M
Total Assets
145.38 M
Total Liabilities
110.28 M
Equity
35.10 M
-4.27 %
Week
14.81 %
1 Month
15.41 %
3 Month
-1.26 %
6 Month
-95.56 %
5 Year
-95.56 %
All Time
Cash Data
Cash Position
31.98 M
Monthly Burn
4.38 M
Runway
4.8 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
374.48 K
52 Week Range
12.30 - 188
% held by Insiders
57.24 %
% held by Institutions
35.4 %
Enterprise Value
113.37 M
Total Shares
3.35 M
Short %
4.59 %
Float Shares
1.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pelthos Therapeutics Inc.
76Total events
6Upcoming
20Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-01-05 | Zelsuvmi (berdazimer sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-01-05 | Zelsuvmi (berdazimer sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-01-05 | Zelsuvmi (berdazimer sodium) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PTHS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PTHS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PTHS▼ -6.4%on this news
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Pelthos Therapeutics Inc. will report its second quarter 2026 financial results on August 13, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results, followed by a Q&A session. Pelthos is known for its innovative treatments for cutaneous infectious diseases.
Read more →PTHS▲ +6.4%on this news
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders to be held virtually on September 29, 2026. Stockholders of record by August 4, 2026, will be eligible to vote. The meeting date has changed by more than 30 days from the previous year, affecting the submission of stockholder proposals.
Read more →PTHSPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. has been added to the Russell 3000E Growth Benchmark and other Russell indexes effective June 29, 2026. This inclusion reflects the company's growth and strategic advancements since becoming public. CEO Scott Plesha expressed optimism that this will increase the company's visibility and investment opportunities.
Read more →PTHSPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. has been added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark Indexes as of June 29, 2026. This inclusion is part of the 2026 Russell indexes reconstitution, which ranks the largest US stocks by market capitalization. CEO Scott Plesha expressed optimism about the company's visibility and growth opportunities following this milestone.
Read more →PTHSPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Scott Plesha is scheduled to present and engage in one-on-one investor meetings. The company is dedicated to developing therapeutic products for infectious diseases, including its lead product ZELSUVMI® for molluscum contagiosum.
Read more →PTHSLegal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other secu
Pelthos Therapeutics Inc. presented at the Jefferies Global Healthcare Conference, highlighting its focus on innovative dermatological products. The company has launched Zelsuvmi, a treatment for molluscum contagiosum, and it anticipates further product launches in the pipeline, including Xepi and Xeglyze. The management team has significant experience within the pharmaceutical industry, which supports the firm's development strategy amid potential market challenges.
Read more →PTHS▲ +6.5%on this news
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Pelthos Therapeutics reported a 17% increase in ZELSUVMI revenue for Q1 2026, reaching $10.7 million. The company dispensed 7,884 units, marking a 25% rise from the previous quarter. Management expressed optimism about ongoing growth, supported by a strengthened sales force and a new $50 million loan facility. However, the company also reported a net loss of $(10.2) million.
Read more →PTHSPelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
Pelthos Therapeutics Inc. has announced that it will report its first quarter 2026 financial results on May 14, 2026. The company will host a conference call at 8:30 a.m. Eastern time to discuss these results, allowing for a question-and-answer session afterwards. Pelthos is focused on innovative therapies for cutaneous infectious diseases, including its lead product ZELSUVMI™. Additional details about the conference call and corporate information were also provided in the announcement.
Read more →PTHSPelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Pelthos Therapeutics Inc. announced participation in the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston. CEO Scott Plesha is set to hold one-on-one investor meetings, signaling the company's commitment to engaging with potential investors. Pelthos focuses on innovative treatments for infectious diseases, with its leading product being ZELSUVMI™, a topical gel approved for home use against Molluscum contagiosum. This event may enhance the company's visibility and focus on unmet patient needs.
Read more →PTHSPelthos Therapeutics Announces CFO Transition
Pelthos Therapeutics Inc. announced the appointment of John M. Gay as the new Chief Financial Officer, effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II and previously served as Senior Vice President, Finance & Accounting at Pelthos. CEO Scott Plesha expressed confidence in Gay's capabilities to support the company's ongoing growth and praised Knuettel's contributions post-merger with Channel Therapeutics. Pelthos focuses on innovative therapeutics for infectious diseases, notably ZELSUVMI™ for Molluscum contagiosum.
Read more →PTHSPelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics has announced the dosing of the first patient in a Phase 1b/2a clinical trial for CT2000, intended to treat eye pain associated with dry eye disease. This marks the first human trial for CT2000, which has shown promising results in pre-clinical animal studies. The trial will assess the safety and clinical efficacy of the eye drop formulation. Results are expected by the end of 2026, highlighting the potential value of CT2000 in addressing unmet therapeutic needs in eye care.
Read more →PTHSPelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
Pelthos Therapeutics reported a significant growth in net product revenue for its product ZELSUVMI, achieving $9.1 million in the fourth quarter of 2025. The company also highlighted a remarkable 129% increase in units of ZELSUVMI dispensed from the third to fourth quarters. Pelthos has broadened its product offerings with the acquisition of XEPI and XEGLYZE, enhancing its portfolio in the dermatology sector. CEO Scott Plesha expressed confidence in ongoing growth strategies supported by recent financial activities, including significant private financing and a senior secured term loan.
Read more →PTHS▲ +5.4%on this news
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026. Investors can arrange one-on-one meetings through ROTH representatives. A live webcast of the chat will be available on the company's website, with a replay accessible for 90 days post-event.
Read more →PTHSPelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Pelthos Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results on March 19, 2026. The announcement includes a conference call scheduled for 8:00 a.m. Eastern Time, allowing for a question-and-answer session. The company is recognized for its commitment to developing therapies for infectious diseases.
Read more →PTHS▲ +5%on this news
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The management team will also host one-on-one meetings with investors during the event. The presentation will be available via webcast and on the company's website.
Read more →PTHSPelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance. This funding will support the commercialization of its lead product, ZELSUVMI, an FDA-approved treatment for molluscum contagiosum, along with other products. The deal is designed to be minimally dilutive to existing shareholders and aims to strengthen Pelthos' balance sheet.
Read more →PTHSCorporate Presentation Q1 2026 2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Lit
Pelthos Therapeutics Inc. has released a corporate presentation highlighting its innovative product, Zelsuvmi, which launched in July 2025 as the first at-home treatment for Molluscum contagiosum. The presentation outlines a strong market potential with an anticipated revenue of $175 million by 2028 from this product alone. The company has also made strategic acquisitions, including FDA-approved dermatological products Xepi and Xeglyze, to enhance its portfolio. An experienced management team backs these initiatives, aiming to establish a significant presence in the biopharmaceutical market.
Read more →PTHS▼ -9%on this news
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Pelthos Therapeutics has acquired Xeglyze® (abametapir) from Hatchtech for $1.8 million. This FDA-approved treatment for head lice is expected to be relaunched in 2027. The acquisition strengthens Pelthos's portfolio and aligns with its strategy to address unmet patient needs. Xeglyze's unique formulation allows for effective treatment with a single application.
Read more →PTHS▼ -9%on this newsshared move
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Pelthos Therapeutics has acquired Xeglyze (abametapir), an FDA-approved treatment for head lice, from Hatchtech for $1.8 million. This acquisition enhances Pelthos' product portfolio and allows for worldwide commercialization. Xeglyze is notable for its single, 10-minute application, which is expected to be relaunched in 2027. The product addresses a significant need in treating head lice infestations.
Read more →PTHS▼ -9%on this newsshared move
Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescript
Pelthos Therapeutics Inc. has acquired Xeglyze, an FDA-approved topical treatment for head lice, from Hatchtech for $1.8 million. This acquisition allows Pelthos to commercialize Xeglyze globally without future milestone or royalty payments. Xeglyze is differentiated by its single application protocol, offering effective lice and egg elimination. The company plans to relaunch the product in the first half of 2027, aiming to address the common issue of head lice infestations prevalent in children.
Read more →PTHSPelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Pelthos Therapeutics has appointed Andrew J. Einhorn to its Board of Directors, effective immediately. With over 40 years of experience in finance and life sciences, Einhorn will also serve on the Audit and Compensation Committees. His expertise is expected to support Pelthos's growth as a commercially focused biopharmaceutical company.
Read more →PTHSPelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn Seasoned executive brings four decades of finance, capital markets, and life sciences experience DURHAM, N.C.
Pelthos Therapeutics Inc. has expanded its Board of Directors by appointing Andrew Einhorn, a seasoned finance executive with over 40 years of experience. Einhorn will also serve on the Audit and Compensation Committees. His extensive background in investment banking and life sciences is expected to aid Pelthos in its growth as a commercially focused biopharmaceutical company. The appointment follows the recent approval of the company's lead product, ZELSUVMI, for treating molluscum contagiosum.
Read more →PTHSPelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics has entered into a commercial agreement with a major Pharmacy Benefit Manager to enhance patient access to ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum. This agreement, effective from December 1, 2025, aims to improve coverage and distribution for the topical gel, which is suitable for both adults and pediatric patients. The CEO emphasized the importance of this partnership in providing treatment options for those affected by this contagious skin condition.
Read more →PTHSPelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics has entered into a significant commercial agreement with a major Pharmacy Benefit Manager to expand patient access to its FDA-approved treatment, ZELSUVMI, for molluscum contagiosum. This topical gel, launched in July 2025, is the only approved at-home treatment for the viral skin condition affecting millions. The new agreement aims to enhance coverage and distribution for patients in need, further supporting Pelthos's commitment to addressing unmet medical needs in dermatology.
Read more →PTHSPelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Pelthos Therapeutics announced that its CEO, Scott Plesha, will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The event will take place at The Lotte New York Palace in New York City. Institutional investors have the opportunity to meet one-on-one with Mr. Plesha through their Piper Sandler representatives. For those unable to attend in person, a live webcast will be accessible on the company’s website approximately two hours after the chat.
Read more →PTHS▼ -7.3%on this news
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
Pelthos Therapeutics reported strong financial results for Q3 2025, driven by the successful launch of ZELSUVMI, which generated $7.1 million in net revenues. The product saw significant adoption, with 2,716 units prescribed by 1,169 unique prescribers. The company anticipates continued growth in Q4 2025 and highlights the strategic acquisition of XEPI as a complementary addition to its product line.
Read more →PTHS▼ -8.1%on this news
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Pelthos Therapeutics has acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, a treatment for impetigo, from Biofrontera and Ferrer. The company also secured $18 million in private convertible notes financing to support this acquisition and other product developments. Pelthos plans to relaunch Xepi in late 2026, enhancing its portfolio in pediatric dermatology.
Read more →PTHS▼ -8.1%on this newsshared move
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Pelthos Therapeutics has acquired the U.S. rights to Xepi® (ozenoxacin) Cream, a topical treatment for impetigo, from Biofrontera and Ferrer. The acquisition is supported by an $18 million private convertible notes financing aimed at facilitating the re-launch of Xepi and the commercialization of ZELSUVMI. The company plans to re-launch Xepi in late 2026, addressing a significant need in pediatric dermatology.
Read more →PTHS▼ -8.1%on this newsshared move
Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing Acquisition adds complementary dermatology product to the Pelthos portfolio an
Pelthos Therapeutics has acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, intending to address pediatric dermatology needs. The company also closed on an $18 million private convertible notes financing facilitated by existing investors. The acquisition agreement includes upfront payments and additional royalties based on sales milestones. Xepi, effective against antibiotic-resistant strains, will be relaunched in late 2026, capitalizing on the growing demand for alternative treatments for impetigo in children.
Read more →PTHS▲ +6.5%on this newsshared move
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
Pelthos Therapeutics Inc. is set to report its third quarter 2025 financial results on November 13, 2025. The announcement includes a conference call scheduled for 8:00 a.m. Eastern Time, where management will discuss the quarter's performance. The results will be released prior to the call, allowing for a detailed analysis of the company's financial standing. Pelthos is focused on innovative therapeutic solutions for patients with unmet treatment needs, having launched its product ZELSUVMI, approved in 2024 for molluscum contagiosum.
Read more →PTHS▲ +15.9%on this news
Corporate Presentation Q 4 2 02 5 1 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities
Pelthos Therapeutics Inc. is set to launch Zelsuvmi in July 2025 for the treatment of Molluscum contagiosum, targeting a significant market with around 16.7 million affected people annually. The company underscores its strong management team, experienced in launching multiple drugs successfully. However, it also highlights inherent uncertainties and risks, particularly regarding the success of clinical trials and market acceptance of Zelsuvmi. The total addressable market for this innovative treatment exceeds $20 billion, reflecting the unmet medical need in this area.
Read more →PTHS▼ -7.9%on this newsshared move
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
Pelthos Therapeutics has launched the Moms Against Molluscum movement to unite families affected by molluscum contagiosum, a highly contagious skin infection. The initiative aims to provide support and information about treatment options, particularly ZELSUVMI, a topical gel recently approved by the FDA. The movement encourages open discussions among caregivers to alleviate the emotional burden of the condition.
Read more →PTHSLNHC, Inc. Condensed Balance Sheets (in thousands) (Unaudited)
LNHC, Inc. reported its condensed balance sheets and statements of operations for the period ending June 30, 2025. The company showed a significant increase in total current assets, cash, and revenue compared to the prior year. However, it also faced a notable increase in operating losses and total liabilities, leading to a significant net loss for the period. The financial health of LNHC appears challenging despite some positive asset growth.
Read more →PTHS▲ +14%on this news
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
Pelthos Therapeutics Inc. will participate in two upcoming investor conferences in September 2025. CEO Scott Plesha and CFO Frank Knuettel II will represent the company at the H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. The events provide opportunities for one-on-one meetings with institutional investors and will feature a webcast of their presentation.
Read more →PTHS▲ +23.8%on this news· ran to +45% by day 1shared move
Q 3 2 0 2 5 1 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act
Pelthos Therapeutics Inc. presented its forward-looking statements, primarily focusing on the upcoming launch of Zelsuvmi, the first at-home treatment for Molluscum contagiosum scheduled for July 2025. The company highlights the significant market potential, with a total addressable market exceeding $20 billion. It seeks to leverage its experienced management team to navigate the challenges of market entry and ongoing development. However, the company also acknowledges several risks and uncertainties that could affect its future performance and product acceptance.
Read more →PTHS▼ -5%on this news· ran to +19% by day 3shared move
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Pelthos Therapeutics Inc. will participate in the Wells Fargo Healthcare Conference on September 3, 2025. CEO Scott Plesha and CFO Frank Knuettel will present at the event. The company focuses on innovative therapeutic products and has recently received FDA approval for its lead product, ZELSUVMI™. A webcast of the presentation will be available on their website.
Read more →PTHSPelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Pelthos Therapeutics reported its second quarter 2025 financial results, marking the last report solely for legacy operations before its merger with Channel Therapeutics. The company successfully launched ZELSUVMI, the first FDA-approved topical treatment for molluscum contagiosum, and has built a commercial team to support its growth. The CEO expressed optimism about future growth and expansion of their product pipeline.
Read more →PTHS▲ +60.8%on this news
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
Pelthos Therapeutics has launched ZELSUVMI™ (berdazimer) topical gel, the first FDA-approved at-home treatment for molluscum contagiosum. This innovative gel is designed for use in adults and children over one year old, providing an effective and convenient treatment option. Clinical trials showed nearly 33% of patients achieved complete clearance of lesions within 12 weeks. The company aims to support patients through education and a dedicated patient support program.
Read more →PTHS▲ +60.8%on this newsshared move
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
Pelthos Therapeutics has launched ZELSUVMI™ (berdazimer) topical gel, the first FDA-approved at-home treatment for molluscum contagiosum. This once-daily prescription medication is designed for use by patients, parents, and caregivers. The gel was shown to be effective in a Phase 3 clinical trial, achieving nearly 33% clearance of lesions by week twelve. The launch aims to provide a much-needed treatment option for millions affected by this viral skin condition.
Read more →PTHSPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Pelthos Therapeutics has successfully completed its merger with Channel Therapeutics and closed a $50.1 million private placement. The newly formed entity will focus on launching ZELSUVMI™, a topical gel for treating molluscum contagiosum, in July 2025. This merger positions Pelthos for future growth and aims to address significant patient needs.
Read more →PTHSChannel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Channel Therapeutics Corporation announced a 10-for-one reverse stock split to increase its share price and meet NYSE listing requirements. This move coincides with the anticipated merger with LNHC, which includes a $50 million capital raise from strategic investors. The reverse split will take effect on July 1, 2025, with trading under the new name Pelthos Therapeutics Inc. starting July 2, 2025.
Read more →PTHSChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules FREEHOLD, N.J.
Channel Therapeutics Corporation provided an announcement regarding compliance with NYSE American listing rules related to its 2024 Annual Report. The report, filed with the SEC, included an audit opinion emphasizing concerns regarding the company's financial viability. This information is essential for transparency in the company's business operations. While there are no changes to the consolidated financial statements, the going concern issue underscores challenges ahead for the company.
Read more →PTHSLigand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Pharmaceuticals and Channel Therapeutics have announced a merger agreement to combine their subsidiaries, Pelthos Therapeutics and LNHC, Inc. This merger aims to accelerate the commercialization of ZELSUVMI, the first FDA-approved home treatment for molluscum contagiosum. The transaction is expected to close in the summer of 2025 and will raise $50 million in equity capital.
Read more →PTHSOT Pelthos Therapeuties Corporate Corporate Presentation Presentation Q 2 2 0 2 5 SO) NSD) NaN CONFIDENTIAL 1 Disclaimers Important Information for Investors This confidential presentation ("Presentation") is for informa
Pelthos Therapeutics has provided a confidential corporate presentation to potential investors for evaluating a private securities offering. This presentation outlines a proposed business combination between Channel Therapeutics Corporation and LNHC Inc., involving Pelthos Therapeutics. The information contained in the presentation includes financial estimates and performance expectations but makes no guarantees regarding the accuracy of these projections. This document serves as an introductory tool for investors considering participation in the proposed transaction.
Read more →PTHSChromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates "Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodiu
Chromocell Therapeutics Corporation has officially changed its name to Channel Therapeutics Corporation, effective November 18, 2024. The rebranding aims to signify the company's emphasis on developing non-opioid therapeutics targeting sodium channels for pain treatment. CEO Frank Knuettel II commented on the potential of their sodium channel target, NaV1.7, emphasizing the advancements the company is making in their pain therapeutic programs. Additionally, by reincorporating in Nevada, the company anticipates reduced tax rates and increased strategic flexibility.
Read more →PTHSChromocell Announces Stock Repurchase Plan FREEHOLD, N.J.
Chromocell Therapeutics Corporation has announced an amendment to its existing stock repurchase plan, increasing the total buyback value from $250,000 to $750,000. This amendment extends the plan's termination date to June 30, 2025. The CEO expressed confidence that the company's common stock is undervalued, viewing it as an attractive investment. However, the plan does not obligate the company to repurchase any specific amount of stock and is subject to market conditions and management discretion.
Read more →PTHSCHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies CHROMOCELL THERAPEUTICS CORPORATION 2 This presentation of Chromocell Therapeu
Chromocell Therapeutics Corporation is advancing its potential breakthrough drug, CC8464, aimed at treating non-opioid pain therapies. The company focuses on modulating NaV1.7 receptors, which are integral in pain signaling. With substantial preclinical results showing promise, especially in idiopathic small fiber neuropathy and erythromelalgia, it has a well-experienced team leading its development. However, the company faces risks related to regulatory approvals and commercialization strategies.
Read more →PTHSPelthos Therapeutics Establishes Board of Directors
Pelthos Therapeutics has appointed five new members to its Board of Directors, enhancing its leadership team as it approaches a critical phase in its development. The new board members bring extensive experience in the biopharmaceutical industry, which is expected to support Pelthos in advancing its therapeutic products. CEO Scott Plesha expressed confidence in the board's ability to guide the company through its next steps.
Read more →PTHSChromocell Issues Letter to Stockholders from Chief Executive Officer FREEHOLD, N.J.
Chromocell Therapeutics has updated stakeholders following its successful IPO that raised $6.6 million. CEO Frank Knuettel outlined the company's plans to accelerate the development of non-opioid pain treatments, including the lead compound CC8464, which has shown promising Phase I trial results. The firm aims to address various pain indications while also exploring ocular pain treatments and expanding its therapeutic pipeline. Despite facing side effects in trials and a delay in the 10-K filing, the company believes it is positioned for long-term growth.
Read more →PTHSLigand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals has launched Pelthos Therapeutics, appointing Scott Plesha as CEO. The new company aims to commercialize ZELSUVMI, a topical gel for molluscum contagiosum, expected to be available in late 2024. This product is notable for being the first at-home treatment approved for this condition. Ligand acquired the rights to ZELSUVMI from Novan, Inc. in September 2023.
Read more →PTHSChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler New Program Targets Estimated $2.5 Billion Eye Pain Market Freehold, New Jersey
Chromocell Therapeutics has officially launched its eye pain treatment program, aiming to address a cosmetic market estimated at $2.5 billion. This initiative is propelled by the hiring of Dr. Simon Chandler, an expert in ophthalmic drug development. The program focuses on sodium channel NaV1.7 to treat various eye pain indications, including conditions like corneal abrasions. While the potential market opportunity is significant, Chromocell faces challenges like competition and the need for effective commercialization strategies.
Read more →PTHSChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 Freehold, New Jersey
Chromocell Therapeutics Corp. has named Frank Knuettel as its permanent Chief Executive Officer, a title he held in an interim capacity since July 2023. Knuettel, who also serves as CFO, aims to advance the company's efforts in developing non-opioid pain treatment therapies. The board of directors expressed confidence in his leadership skills and strategic perspective, supporting his vision for the company's clinical and pre-clinical programs.
Read more →PTHSCHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non - Opioid Pain Treatment Therapies CHROMOCELL THERAPEUTICS CORPORATION 2 Legal Disclaimer This presentation of
Chromocell Therapeutics Corporation is advancing the development of CC 8464, a novel non-opioid pain treatment therapy. The therapy has successfully completed clinical Phase 1 trials and is positioned to address a significant market driven by the opioid crisis. With a focus on non-opioid pain management, the company is exploring partnerships while facing certain regulatory and safety challenges as it progresses. Chromocell's strategy includes leveraging its patented compound and planning for potential out-licensing opportunities following further clinical success.
Read more →PTHSChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering Freehold, NJ
Chromocell Therapeutics Corporation has announced the pricing of its upsized initial public offering (IPO), raising $6.6 million through the sale of 1,100,000 shares at $6.00 each. The offering is set to close on February 21, 2024, pending customary conditions, and the company will list its shares on the NYSE American under the symbol 'CHRO.' The net proceeds from the IPO will be used for several clinical studies involving their lead product, CC8464, aimed at treating various pain conditions. This move reflects Chromocell's ongoing commitment to developing non-opioid therapeutics for pain management.
Read more →Competitive Position
How PTHS ranks across every disease it competes inCompetitive Position is a premium feature
See how PTHS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial